

Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast Cancer

Best Practices for Adverse Event Management and Patient Education

Activity Description

This initiative is designed to increase the knowledge and competence of nurse practitioners, physician assistants, nurses, and nurse navigators with regards to the optimal utilization of TROP2-targeting ADCs in TNBC and HR+, HER2- breast cancer in the context of current evidence and expert recommendations. It aims to provide guidance on best practices for adverse event management and patient education. Additionally, patient-directed tools and resources developed in collaboration with patient advocacy partners, Guiding Researchers and Advocates to Scientific Partnerships (GRASP) and the Chrysalis Initiative, will be provided.

Target Audience

This activity has been designed to meet the educational needs of nurse practitioners, physician assistants, nurses, nurse navigators, patients/caregivers, and other healthcare professionals involved in the care of patients with TNBC and HR+, HER2-breast cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

- Describe the efficacy and safety profiles and current clinical roles of TROP-targeting ADCs in TNBC and HR+, HER2- MBC
- Mitigate adverse events associated with different TROP2-targeting ADCs in TNBC and HR+, HER2- MBC
- Apply best practices for patient education and provision of team-based, patient-centric, equitable care to all patients with TNBC and HR+, HER2- MBC, including those in underserved communities

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Accreditation, Support, and Credit



In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP, and The Chrysalis Initiative. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

ILNA Coding Statement

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points as follows:

The numerical value(s) indicated above is the maximum amount of points that can be claimed in each subject area domain. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential being renewed.

PeerView
Live



This NCPD/AAPA activity is provided by PVI, PeerView Institute for Medical Education.
This activity has been developed in partnership with GRASP and The Chrysalis Initiative.
This activity is supported by an independent educational grant from Gilead Sciences, Inc.




[PeerView.com/BreastCancer-Survey-USZ](https://www.peerview.com/BreastCancer-Survey-USZ)

Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast Cancer

Best Practices for Adverse Event Management and Patient Education

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Physician Assistants

 PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to *The Standards for Integrity and Independence in Accredited Continuing Education*. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Chair/Planner

Jamie Carroll, APRN, CNP, MSN
Assistant Professor of Oncology
Nurse Practitioner
Mayo Clinic
Rochester, Minnesota

Jamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzena.
Speakers Bureau participant with Curio Science.

Faculty/Planner

Loyda Braithwaite, MSN, APRN, AGPCNP-BC, AOCNP, ACHPN
Oncology Nurse Practitioner
University of Wisconsin
Carbone Cancer Center
Madison, Wisconsin

Loyda Braithwaite, MSN, APRN, AGPCNP-BC, AOCNP, ACHPN, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This NCPD/AAPA Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

PeerView
Live



This NCPD/AAPA activity is provided by PVI, PeerView Institute for Medical Education.
This activity has been developed in partnership with GRASP and The Chrysalis Initiative.
This activity is supported by an independent educational grant from Gilead Sciences, Inc.



[PeerView.com/BreastCancer-Survey-USZ](https://www.peerview.com/BreastCancer-Survey-USZ)